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Abstract: Background and Objectives: The use of the dopamine-partial agonist subclass (also termed
dopamine stabilizers) of atypical antipsychotics for the treatment of negative schizophrenia symptoms
and some mood disorders has increased recently. Similar to other second-generation antipsychotics
(SGAs), aripiprazole (ARI) and cariprazine (CAR) also influence food intake, but the peripheral
effects of these drugs on adipose–tissue homeostasis, including adipokine secretion as well as
lipo- and adipogenesis, are not fully elucidated. In this study, we explored the adipocyte-related
mechanisms induced by second-generation antipsychotics (SGAs), leading to changes in peripheral
signals involved in energy homeostasis. Materials and Methods: CAR, a new SGA, was compared with
ARI and olanzapine (OLA), using cell cultures to study adipogenesis, and the expression levels of
peroxisome proliferator-activated receptor-γ (PPAR-γ) was measured in adipocytes derived from
mouse fibroblasts, by western blotting on days 7, 14, and 21 postinduction. The triglyceride (TG)
content of the cells was also evaluated on day 15 using Oil Red O staining, and the adiponectin
(AN) content in the cell culture supernatants was quantified on days 7 and 15 by enzyme-linked
immunosorbent assay. Cells were treated with two concentrations of ARI (0.5 and 20 µg/mL),
OLA (1 and 20 µg/mL), and CAR (0.1 and 2 µg/mL). Results: Both concentrations of ARI and OLA,
as well as the lower concentration of CAR, significantly increased the TG contents. The AN levels
in the supernatants were significantly increased by the higher concentration of ARI on days 7 and
15 (p < 0.05). Although PPAR-γ levels were not significantly affected by ARI and OLA, the lower
concentration of CAR induced a significant time-dependent decrease in PPAR-γ expression (p < 0.05).
Conclusions: The in vitro adipogenesis considered from TG accumulation, AN secretion, and PPAR-γ
expression was differently influenced by ARI, CAR, and OLA. Understanding the adipocyte-related
mechanisms of antipsychotics could contribute to understanding their weight-influencing effect.
Keywords: adipogenesis; triglyceride accumulation; peroxisome proliferator-activated receptor-γ
expression; adiponectin; antipsychotics
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1. Introduction
Second-generation antipsychotics (SGAs) include newer agents used in the treatment of several
psychiatric diseases, and are considered to be different from older drugs (also called classical or typical
antipsychotics). These agents are also thought to be more favorable in terms of efficacy and side
effects; for example, SGAs do not induce the characteristic extrapyramidal side effects (EPS) and are
more effective in treating the negative signs of schizophrenia [1–4]. Although SGAs do not induce
the most commonly reported adverse effects of first-generation antipsychotics (e.g., EPS, sedation,
cardiovascular effects, anticholinergic effects, and hyperprolactinemia), they are characterized by
metabolic effects, such as weight gain, increased blood glucose, and increased plasma lipid levels [4].
Weight gain is not thought to be dose-dependent within the normal therapeutic dose range, whereas the
glycemic abnormalities may comprise mild (e.g., worsening of insulin resistance in patients with already
compromised glycemic control) to very severe forms of ketoacidosis or hyperosmolar coma [4,5].
Based on extensive evidence published to date, different SGAs show varying inductions of
adverse metabolic events [5–10]. The proposed mechanisms of antipsychotic-induced weight gain
involve multiple pathways, including antagonism of 5HT2C, H1, and D2 receptors associated with
increased insulin resistance, as well as reduced glucose uptake by skeletal muscles [11]. The most
prominent effects are produced by olanzapine (OLA) and clozapine, whereas much lower or even
unnoticeable effects are observed following treatment with amisulpride or aripiprazole (ARI), which
can be considered “metabolically neutral” under certain circumstances [6,7,9,12]. Notably, the molecular
pharmacology of SGAs varies greatly in terms of binding profiles and having very different effects on
various serotonergic (5-HT), dopaminergic, histaminergic (H), adrenergic, and cholinergic receptors [13].
Some authors consider the H1 receptor affinity as the most important predictor of short-term weight
gain [14]. Correspondingly, the most orexigenic SGA (i.e., OLA) is a 5HT2C and H1 antagonist with high
affinity (Ki = 6.8 and 2 nM for 5HT2C and H1, respectively) [14,15]. ARI and cariprazine (CAR) have
considerably lower affinity towards these receptors (Ki = 15 and 61 nM for 5HT2C and H1, respectively,
for ARI; Ki = 134 and 23.2 nM for 5HT2C and H1, respectively, for CAR) [16]. Moreover, ARI and CAR
are both partial agonists at D2 and D3—the main difference between them being that CAR has nearly
10-fold higher affinity towards D3 than D2 [16]. This can partially explain the metabolic differences
between CAR and ARI.
Adipose tissue is no longer considered an inert organ, and is now known to have a role in storing
energy in the form of triglycerides (TGs) [17]. Moreover, the adipose tissue secretes bioactive signaling
molecules, mainly proteins, being a part of the endocrine signaling system. These molecules are
commonly termed “adipokines”, indicating factors that are secreted by adipocytes and delivered
to the systemic circulation. Adiponectin (AN) is an important adipokine whose concentration is
inversely related to adiposity and insulin resistance [18]. Indeed, hypoadiponectinemia is associated
with dyslipidemia, hypertension, oxidative stress, and a carbohydrate-rich diet [19,20]. Furthermore,
administration of AN improves insulin sensitivity both under in vitro and in vivo conditions through
various mechanisms, e.g., increasing glucose utilization in muscle, inducing fatty acid oxidation in
hepatic cells, and decreasing hepatic glucose production; it also decreases body weight in vivo [21–23].
These effects are at least partially mediated by a peroxisome proliferator-activated receptor (PPAR)-α,
which is involved in the regulation of many genes in different metabolic pathways (e.g., fatty acid
oxidation, mitochondrial biogenesis, glucose homeostasis, and inflammation) [18,24].
PPARs are members of the nuclear hormone receptor superfamily, comprising ligand-activated
transcription factors that bind to the promoter regions of certain genes and then increase or decrease
DNA transcription [25]. PPAR-γ is the main factor involved in adipogenesis and is essential for
differentiation; indeed, lack of PPAR-γ expression blocks the differentiation of pre-adipocytes into
mature adipocytes [25]. During adipocyte differentiation, the expression of PPAR-γ is markedly
increased, thereby promoting differentiation [26]. A number of endogenous ligands bind to PPAR-γ,
including fatty acids, prostaglandins, and oxidized phospholipids, and several exogenous compounds,
including thiazolidindiones, which enhance insulin sensitivity, are used in the treatment of diabetes
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mellitus. Some SGAs (OLA, clozapine, risperidone) induce the expression of sterol regulatory
element-binding protein (SREBP), leading to enhanced lipogenesis and adipogenesis [27–29]. Notably,
crosstalk between SREBP and PPAR-γ activation has also been demonstrated [30]. Furthermore,
OLA directly stimulates the expression and activation of PPAR-γ (although to a lesser extent than that
of SREBP-1) [27]. Interestingly, the expression levels of genes encoding PPAR-γ and PPAR-α are two-
to three-fold higher in human adipose tissue-derived stem cells under in vitro conditions after SGA
treatment [31]. To the best of our knowledge, no studies have reported the expression of these key
adipogenesis factors after CAR treatment or compared the three SGAs.
As recently hypothesized, adipocytes are potential sources of metabolic abnormalities, as observed
in SGA-induced metabolic syndrome (MS) [12]. Therefore, in order to assess the contributions of
adipocytes to MS, we measured the expression of PPAR-γ, the TG contents of adipocytes, and the AN
concentrations of cell culture supernatants during in vitro adipogenesis. Additionally, to evaluate the
involvement of CAR in metabolic regulation at the adipocyte level, the results were compared with
those of OLA and ARI—i.e., SGAs with the least and most favorable metabolic profiles, respectively.
2. Materials and Methods
2.1. Cell Culture
The effects of the three SGAs on adipogenesis were studied using mouse embryonic fibroblasts
(MEFs). The cell culture was established according to previously published protocol [32]. Cells were
cultured to confluency in Dulbecco’s modified Eagle’s medium (DMEM) containing 4 g/L glucose, 10%
fetal bovine serum (FBS), and 8 µg/dL gentamicin. Differentiation of two-day post-confluent fibroblast
cultures was then initiated by addition the induction solution (IND) (0.2 mM isobutylmethylxanthine
(IBMX), 0.5 µM dexamethasone, 10 µg/dL insulin, and 10 µM pioglitazone), for two days. Following
the two-day induction, the cell lines were refed every two days with the maintenance medium
(DMEM + 10% FBS + 10 µg/dL insulin) plus the SGAs at two concentrations (ARI: 0.5 and 20 µM;
CAR: 0.1 and 2 µM; OLA: 1 and 20 µM). The lower concentrations of drugs were chosen to be
similar or slightly greater than the plasma concentrations seen in normal clinical settings. In this case,
the plasma concentration for ARI was 0.47 ± 0.31 µM (for doses of 20 ± 8 mg/day), for OLA it was
0.11 ± 0.08 µM (for doses of 14.2 ± 5.4 mg/day), and for CAR it was about 0.1 µM (for a typical dose of
9 mg/day) [33–35]. The higher concentrations of the drugs were chosen in order to maximize the effect
of the drugs on the process of adipogenesis, without affecting the viability of the cells. The experiment
lasted for 15 days for AN and TG measurement, or 21 days for PPAR-γ assays. As a negative control,
only IND was added.
2.2. Triglyceride Content Determination of Adipocytes
Assessment of the TG content of the adipocytes was performed on day 15 postinduction and was
used as an indicator of the lipid contents of the cells at the middle stage of adipogenesis. The technique
chosen for TG measurement was staining with Oil Red O, followed by spectrophotometry. Briefly,
the cells were fixed in 8% paraformaldehyde solution for 1 h, washed with distilled water and
60% isopropanol two times, and dried. Cells then were stained with 0.35% Oil Red O solution in
isopropanol. After removing the excess stain by washing four times with distilled water, the retained
stain was extracted to isopropanol, and its concentration was determined by measuring its absorbance
at 500 nm. Because the absorbance of the extract is proportional to the concentration in the Oil Red O
stain (which was bound to the lipids within the cells), the absorbance had a direct relationship with the
amount of TG accumulated in the cells [36].
2.3. Adiponectin Concentration of Cell Culture Supernatant
The AN concentration was determined using a specific enzyme-linked immunosorbent assay
(ELISA) kit on days 7 and 15, using the cell culture supernatants (calibration range: 0–12 ng/mL).
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The Novex ELISA kit (KMP0041) was obtained from Thermo-Fisher Scientific (Waltham, MA,
United States) and was used according to the recommendations of the manufacturer.
2.4. Peroxisome Proliferator-Activated Receptor-γ Expression
The expression of PPAR-γ was assayed by western blotting on days 7, 14, and 21.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is ubiquitously expressed in most cell
types and is therefore a robust standard for western blot measurements, was used as a loading control.
Total cell lysates were prepared using a radio-immunoprecipitation assay buffer containing 50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate (SDS). After denaturation by heating at 95 ◦C for 5 min in Laemmli buffer
(0.1% 2-mercaptoethanol, 0.0005% bromophenol blue, 10% glycerol, 2% SDS, and 63 mM Tris-HCl
(pH 6.8)), 30 µg of protein samples were separated in 15% SDS-polyacrylamide gels and then transferred
onto polyvinylidene difluoride (PVDF) membranes. Membranes were then blocked with 5% non-fat dry
milk dissolved in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h, and were then probed
overnight with primary antibodies for PPAR-γ (1:500 dilution, sc-7196; Santa-Cruz Biotechnology,
Dallas, TX, United States) or GAPDH (1:10,000 dilution, MAB5718; R&D Systems, Minneapolis,
MN, United States) in the same solution at 4 ◦C. After washing with TBST three times, membranes
were incubated with 1:2000 diluted HRP-conjugated secondary antibody for 1 h at room temperature.
The proteins were detected on autoradiography films using enhanced chemiluminescence (ECL)
reagent. The films were scanned, and the obtained images were evaluated using ImageJ software
(v. 1.51j8, National Institute of Health, Bethesda, MD, United States), and the amount of protein was
proportional to the size of the black spots. The quantity of PPAR-γ was expressed as the ratio of PPAR-γ
to GAPDH.
2.5. Statistical Analysis
The results were analyzed with GraphPad Prism 5, and the level of statistical significance was set
at α = 0.05 for all tests. Two-way ANOVA with Dunnett’s post-hoc test was used to test the influence
of treatment and dose on the TG content of adipocytes. A three-way ANOVA with Dunnett’s multiple
comparisons test was performed to assess the influence of treatment, dose, and time on AN content of
the supernatant. For PPAR-γ expression, a two-way ANOVA could not have been performed because of
the low number of measurements (n = 3), and non-Gaussian distribution of the data. In order to assess
the effect of the time and dosage, a series of non-parametric one-way ANOVA, i.e., Kruskall–Wallis
(KW) tests, were performed.
3. Results
3.1. Triglyceride Content of Cells
The results of TG content measurement are summarized in Figure 1.
The two-way ANOVA analysis showed a significant influence caused by the treatment
(F (3, 32) = 40.98; p < 0.0001) and the interaction (F (3, 32) = 47.70; p < 0.0001), but not the dose applied
(F (1, 32) = 2.293; p = 0.1398). The Dunnett’s multiple comparisons test showed that the TG content of
adipocytes was increased significantly by both concentrations of OLA (p < 0.001 for both) and ARI
(p < 0.01 and p < 0.001 for the lower and higher concentrations, respectively), as well as by the lower
concentration of CAR (p < 0.001), compared with the IND group. The 0.1 µM concentration of CAR
robustly increased TG accumulation, giving the highest values, whereas the higher concentration of
the drug produced a value similar to that of the IND group (p > 0.05), the lowest of all treated groups.
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Figure 1. The triglyceride (TG) content of adipocytes after olanzapine (OLA), aripiprazole (ARI), and
cariprazine (CAR) exposure. IND: cell lines induced with Dulbecco’s modified Eagle’s medium (DMEM),
isobutylmethylxanthine (IBMX), insulin (INS), and pioglitazone(PIO). OLA 1 and OLA 20: cell lines
expos d to 1 or 20 µM olanzapine, respectively. ARI 0.5 and ARI 20: cell lines exposed to 0.5 or 20 µM
aripiprazole, res ectively. CAR 0.1 and 2: cell lines exposed to 0.1 or 2 µM cariprazine, respectively.
Data are expressed s the median with minimum and aximum values; level of significance was
set to α = 0.05.
3.2. Adiponec in Contents in Cell Culture Supernatants
A three-way ANOVA showed significant main effects of treatment (F (3, 62) = 13.77, p <
0.001), concentration (F (1, 62) = 5.799, p = 0.019), and time (F (1, 62) = 21.29, p < 0.001) on AN
contents in the cell culture supernatants. Subsequent two-way ANOVAs (treatment × time) showed
that the effect of treatments was n t significant when drugs were applied in low concentrations
(F (3, 31) = 1.953, p > 0.05). However, a Dunnett’s post-hoc t st howed that AN content was
significantly increased by the higher concen ration of ARI on both days 7 and 15 compared with the
IND group (F (3, 31) = 20.96, p < 0.001; see Figure 2). Interestingly, when testing for the effect of time
(two-way ANOVA treatment × dose), there was no influence of the treatment (F (3, 32) = 2.636, p > 0.05)
on day 7, but a significant modification was observed on day 15 in the AN contents in the supernatants
following treatment (F (3, 30) = 18.94, p < 0.001; see Figure 2).
3.3. Peroxisome Proliferator-A tivated Receptor-γ Expression
PPAR-γ protein expression was normalized to GAPDH protein levels. There were no differences
in OLA and ARI groups on any of the testing days. For the CAR groups, a series of non-parametric
one-way ANOVA tests were p rformed, in order to determinate the variation caused by time and
dose. Time caused a significant effect in the case of the CAR 0.1 M group (KW value = 5.815, p < 0.05).
In order to identify the exact source of the difference in time, the Dunn’s multiple comparisons test
was used to compare the mean ranks of CAR groups at days 7 and 21, giving a significant difference
between day 7 and 21 (2.04 ± 0.79 vs. 0.98 ± 0.37, p < 0.05) (Figure 3).
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Figure 3. Expression of PPAR-γ in cell cultures after CAR exposure. IND (7, 14, 21): cell lines
receiving induction solution (DMEM, IBMX, insulin (INS), and pioglitazone (PIO) for 7, 14, and 21 days,
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respectively. Significant changes are noted with * (p < 0.05). Data are expressed as means ± standard
error of mean, and the level of significance was set to α = 0.05.
4. Discussion
In this study, we examined the effects of SGAs on metabolic regulation at the adipocyte level.
Our results showed that these compounds had important effects on TG contents and PPAR-γ expression
in adipocytes.
Notably, we found an increase in the TG contents of adipocytes following SGA exposure, consistent
with previous findings from rat cell lines [12,37]. Interestingly, the 0.1µM concentration of CAR robustly
increased TG accumulation, whereas the higher concentration did not affect TG levels. Although
these data suggest that the lower concentration promoted differentiation, this interpretation must be
made carefully, considering the differences between in vitro and in vivo conditions. Although CAR
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displayed unfavorable effects in this in vitro study, in the clinical setting, CAR induces only modest
or even no weight gain at all, even after chronic treatment [16,35,38]. Our results showed that ARI
and OLA also stimulated adipogenesis. Importantly, exposure to 0.5 µM ARI slightly increased TG
accumulation, displaying a modest but significant effect, whereas the higher concentration of ARI
induced a marked increase in TG contents versus that in the IND group. In one previous study, ARI
was shown to increase the expression of key adipogenesis-related and pro-inflammatory genes [31].
Moreover, ARI markedly decreased TG accumulation in perirenal adipocytes, decreased lipid vacuole
size at lower doses (4 mg/kg), and increased vacuole size at higher doses (8 mg/kg) in rats [39].
The first observation (i.e., the effects of 4 mg/kg ARI) conflicted with clinical reports, whereas the
latter was consistent with clinical results, supporting that ARI is an SGA with a favorable metabolic
profile [6,7,9,11]. OLA, which has been extensively studied, displays a similar increase in TG content,
consistent with previous in vitro findings, suggesting that the adipocyte-related effects of OLA are
important and may contribute to OLA-induced MS [27,31,37,40].
CAR significantly decreased PPAR-γ expression in a time-dependent manner. OLA and ARI did
not influence PPAR-γ expression. Sárvári et al. found that the mRNA levels of PPAR-γ and other
genes were increased after ARI treatment [31]. However, to the best of our knowledge, no studies have
described the amount of PPAR-γ protein expressed in mouse pre-adipocytes. Notably, increase in the
mRNA and protein levels of a gene are not equal, and the translational process is controlled by several
other factors to regulate the end product. Thus, further studies are needed to assess the mechanisms
mediating PPAR-γ expression in this context.
Our results showed that within seven days, the AN content in the supernatant was not influenced
significantly by the treatment. This observation was consistent with previous reports indicating
traceable levels of AN at seven days after induction under in vitro conditions [41]. However, the AN
content in the supernatant increased after exposure to 20 µM ARI on day 15. Interestingly, in all the
other groups, the AN level in cell culture supernatants decreased significantly on day 15 compared with
that on day 7. This was surprising considering that earlier studies demonstrating a steady increase in
AN secretion as adipogenesis proceeds in human mesenchymal stromal cells [41]. The results regarding
AN content in the supernatant highlighted the potential of ARI to induce AN secretion, an adipokine
having beneficial effects, by counteracting insulin resistance and hepatic steatosis through the activation
of glucose utilization in different tissues via adenosine monophosphate (AMP)-activated protein kinase
and PPAR-α activation [18]. Moreover, AN plays an important role in adipose tissue remodeling into
an efficient “metabolic sink”, also improving the sensitivity of adipose tissue to adrenergic stimuli via
the β3 receptor and thus preventing MS [42]. Specifically, AN favored the increase of subcutaneous TG
depots and the decrease of visceral TG [42]. OLA induced an increase in TGs, with a parallel reduction
in supernatant AN content. Inversely, CAR induced TG accumulation markedly when applied at
a low concentration (but not at a high concentration), and did not affect supernatant AN content.
Thus, ARI was found to be an SGA with interesting features—i.e., increasing supernatant AN content
and enhancing TG accumulation.
Although the cell line used in this study may help to elucidate some aspects of adipogenesis as part
of the clinical profile of SGAs, there are some limitations to these conclusions. First, ARI and CAR have
active metabolites presenting high lipophilicity that may contribute to the observed therapeutic effects
(dihydro-aripiprazole, as well as desmethyl- and didesmethyl-cariprazine, respectively) [35,43]. Second,
the AN content in cell culture supernatants do not necessarily reflect secretion of AN from cells, since
the concentration is a net result of the dynamic equilibrium between synthesis and degradation [44].
Third, MEFs are not the standard cell line for studying adipogenesis. The most extensively used is the
3T3-L1 cell line; however, several others, including 3T3-F442A, OP9, and C3H10T1/2 cells have been
described in the literature [45]. Despite these limitations, our data clearly supports that ARI induces
unique time- and dose-dependent increases in AN supernatant concentration. This beneficial effect of
the drug may explain the favorable metabolic profile seen in clinical practice [9,15,16].
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5. Conclusions
Some CNS-acting drugs lack an apparent binding site at the adipocyte level, but nevertheless
may alter adipocyte homeostasis. Although ARI and CAR share some pharmacological targets and
mechanisms involved in the antipsychotic action, they affected the in vitro induced adipogenesis
in mouse fibroblast cells differently: ARI induced TG accumulation, increased AN concentration in
culture supernatants, and did not change PPAR-γ expression; while CAR induced TG accumulation,
did not change AN concentrations, and decreased PPAR-γ expression. However, both drugs
showed some advantages when compared to OLA, which induced TG accumulation, decreased
AN concentration, and did not alter PPAR-γ expression. It can be concluded that a favorable metabolic
profile of an SGA may involve several underlying processes. Some of these are beneficial, others
are not. Nonetheless, the identification of an adipocyte-specific mechanism could contribute to the
understanding of drug-induced weight gain.
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